First Patient Enrolled in GPH101 Trial Testing Potential SCD Cure

First Patient Enrolled in GPH101 Trial Testing Potential SCD Cure

312360

First Patient Enrolled in GPH101 Trial Testing Potential SCD Cure

The first participant has been enrolled in the Phase 1/2 clinical trial CEDAR evaluating Graphite Bio’s investigational gene editing therapy GPH101, which is designed to directly correct the genetic mutation that causes sickle cell disease (SCD). “We are thrilled that our first patient is now enrolled in our CEDAR clinical trial, and we look forward to evaluating GPH101’s potential as we continue to advance its development with urgency in hopes of delivering a curative therapy to…

You must be logged in to read/download the full post.